Literature DB >> 21098697

Expression and functional significance of HtrA1 loss in endometrial cancer.

Sally A Mullany1, Mehdi Moslemi-Kebria, Ramandeep Rattan, Ashwani Khurana, Amy Clayton, Takayo Ota, Andrea Mariani, Karl C Podratz, Jeremy Chien, Viji Shridhar.   

Abstract

PURPOSE: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines. EXPERIMENTAL
DESIGN: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones.
RESULTS: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016).
CONCLUSIONS: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098697      PMCID: PMC3057564          DOI: 10.1158/1078-0432.CCR-09-3069

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

Review 1.  The HtrA family of proteases: implications for protein composition and cell fate.

Authors:  Tim Clausen; Chris Southan; Michael Ehrmann
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

2.  Primary structure of a putative serine protease specific for IGF-binding proteins.

Authors:  J Zumbrunn; B Trueb
Journal:  FEBS Lett       Date:  1996-12-02       Impact factor: 4.124

3.  Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia.

Authors:  L Faccio; C Fusco; A Chen; S Martinotti; J V Bonventre; A S Zervos
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

Review 4.  The HtrA family of serine proteases.

Authors:  M J Pallen; B W Wren
Journal:  Mol Microbiol       Date:  1997-10       Impact factor: 3.501

5.  The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells.

Authors:  Alfonso Baldi; Antonio De Luca; Monica Morini; Tullio Battista; Armando Felsani; Feliciano Baldi; Caterina Catricalà; Ada Amantea; Douglas M Noonan; Adriana Albini; Pier Giorgio Natali; Daniela Lombardi; Marco G Paggi
Journal:  Oncogene       Date:  2002-09-26       Impact factor: 9.867

6.  A web-accessible complete transcriptome of normal human and DMD muscle.

Authors:  Marina Bakay; Po Zhao; Josephine Chen; Eric P Hoffman
Journal:  Neuromuscul Disord       Date:  2002-10       Impact factor: 4.296

7.  A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with placentation.

Authors:  Gui-Ying Nie; Ying Li; Hiroyuki Minoura; Leigh Batten; Guck T Ooi; Jock K Findlay; Lois A Salamonsen
Journal:  Mol Hum Reprod       Date:  2003-05       Impact factor: 4.025

8.  Distribution of the serine protease HtrA1 in normal human tissues.

Authors:  Antonio De Luca; Maria De Falco; Anna Severino; Mara Campioni; Daniele Santini; Feliciano Baldi; Marco G Paggi; Alfonso Baldi
Journal:  J Histochem Cytochem       Date:  2003-10       Impact factor: 2.479

9.  A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer.

Authors:  Jeremy Chien; Julie Staub; Shou-Ih Hu; Michele R Erickson-Johnson; Fergus J Couch; David I Smith; Robert M Crowl; Scott H Kaufmann; Viji Shridhar
Journal:  Oncogene       Date:  2004-02-26       Impact factor: 9.867

10.  Serine protease HtrA1 associates with microtubules and inhibits cell migration.

Authors:  Jeremy Chien; Takayo Ota; Giovanni Aletti; Ravi Shridhar; Mariarosaria Boccellino; Lucio Quagliuolo; Alfonso Baldi; Viji Shridhar
Journal:  Mol Cell Biol       Date:  2009-05-26       Impact factor: 4.272

View more
  17 in total

1.  Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population.

Authors:  Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh
Journal:  Colorectal Cancer       Date:  2017-06-21

2.  Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.

Authors:  Robert Hoffmann; Sayantani Sarkar Bhattacharya; Debarshi Roy; Boris Winterhoff; Ralf Schmidmaier; Keith Dredge; Edward Hammond; Viji Shridhar
Journal:  Biochem Pharmacol       Date:  2020-04-28       Impact factor: 5.858

3.  Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway.

Authors:  Jin Xia; Feng Wang; Liuxing Wang; Qingxia Fan
Journal:  Tumour Biol       Date:  2012-10-19

4.  Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis.

Authors:  Ramandeep Rattan; Rouba Ali Fehmi; Adnan Munkarah
Journal:  J Oncol       Date:  2012-06-04       Impact factor: 4.375

5.  HtrA1 expression associated with the occurrence and development of esophageal cancer.

Authors:  Youtao Yu; Wenlong Shao; Yi Hu; Jingyan Zhang; Hao Song; Zhi-hua Zhu
Journal:  World J Surg Oncol       Date:  2012-08-30       Impact factor: 2.754

6.  Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathways.

Authors:  Ning Wang; Kristin A Eckert; Ali R Zomorrodi; Ping Xin; Weihua Pan; Debra A Shearer; Judith Weisz; Costas D Maranus; Gary A Clawson
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

7.  Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.

Authors:  Laith Farah Al-Rabadi; Tiffany Caza; Claire Trivin-Avillach; Aylin R Rodan; Nicole Andeen; Norifumi Hayashi; Brandi Williams; Monica P Revelo; Fred Clayton; Jo Abraham; Edwin Lin; Willisa Liou; Chang-Jiang Zou; Nirupama Ramkumar; Tim Cummins; Daniel W Wilkey; Issa Kawalit; Christian Herzog; Aaron Storey; Rick Edmondson; Ronald Sjoberg; Tianxin Yang; Jeremy Chien; Michael Merchant; John Arthur; Jon Klein; Chris Larsen; Laurence H Beck
Journal:  J Am Soc Nephrol       Date:  2021-05-05       Impact factor: 14.978

8.  HtrA1: Its future potential as a novel biomarker for cancer.

Authors:  Emma Altobelli; Daniela Marzioni; Amedeo Lattanzi; Paolo Matteo Angeletti
Journal:  Oncol Rep       Date:  2015-05-28       Impact factor: 3.906

9.  Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.

Authors:  Anna Lehner; Viktor Magdolen; Tibor Schuster; Matthias Kotzsch; Marion Kiechle; Alfons Meindl; Fred C G J Sweep; Paul N Span; Eva Gross
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

10.  Multiple sporadic colorectal cancers display a unique methylation phenotype.

Authors:  Victoria Gonzalo; Juan Jose Lozano; Virginia Alonso-Espinaco; Leticia Moreira; Jenifer Muñoz; Maria Pellisé; Sergi Castellví-Bel; Xavier Bessa; Montserrat Andreu; Rosa M Xicola; Xavier Llor; Clara Ruiz-Ponte; Angel Carracedo; Rodrigo Jover; Antoni Castells; Francesc Balaguer
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.